相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First -Pass Lymphatic Drug Sequestration and Long -Acting Pharmacokinetics of the Injectable Triple -HIV Drug Combination TLC -ART 101
Simone Perazzolo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Novel drug combination nanoparticles exhibit enhanced plasma exposure and doseresponsive effects on eliminating breast cancer lung metastasis
Qingxin Mu et al.
PLOS ONE (2020)
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer
Ru Wang et al.
BMC CANCER (2019)
Co-delivery of paclitaxel and gemcitabine via a self-assembling nanoparticle for targeted treatment of breast cancer
Meng Lei et al.
RSC ADVANCES (2019)
Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy
Shiliang Dong et al.
ANTI-CANCER DRUGS (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation
John C. Kraft et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection
Lisa A. McConnachie et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
A Comparative In Vivo Study of Albumin-Coated Paclitaxel Nanocrystals and Abraxane
Joonyoung Park et al.
SMALL (2018)
Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates
Josefin Koehn et al.
AIDS (2018)
Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates
Simone Perazzolo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment
Jing Zhang et al.
MOLECULES (2018)
Liposomal Formulations in Clinical Use: An Updated Review
Upendra Bulbake et al.
PHARMACEUTICS (2017)
Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination
Yi-Nan Zhang et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice
Huan Meng et al.
ACS NANO (2015)
Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure Duration as Well as Triple-Drug Combination Levels in Cells Within Lymph Nodes and Blood in Primates
Jennifer P. Freeling et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2015)
Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer
Ilkoo Noh et al.
BIOMATERIALS (2015)
Stable isotope method to measure drug release from nanomedicines
Sarah Skoczen et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
Sihem Ait-Oudhia et al.
Pharmaceutics (2014)
Combinatorial Drug Conjugation Enables Nanoparticle Dual-Drug Delivery
Santosh Aryal et al.
SMALL (2010)
Why are tumour blood vessels abnormal and why is it important to know?
J. A. Nagy et al.
BRITISH JOURNAL OF CANCER (2009)
Imagable 4T1 model for the study of late stage breast cancer
Kai Tao et al.
BMC CANCER (2008)
Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice
Stephan A. Veltkamp et al.
DRUG METABOLISM AND DISPOSITION (2008)
Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment
Kathy S. Albain et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prolonged versus standard gemcitabine infusion: Translation of molecular pharmacology to new treatment strategy
Stephan A. Veltkamp et al.
ONCOLOGIST (2008)
Albumin-bound paclitaxel: a next-generation taxane
William J. Gradishar
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL
ME de Jonge et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors
JM Reid et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
M Tempero et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Pharmacokinetics of gemcitabine in a patient with end-stage renal disease:: effective clearance of its main metabolite by standard hemodialysis treatment
A Kiani et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma
F Eckel et al.
CANCER INVESTIGATION (2003)
High affinity binding of paclitaxel to human serum albumin
K Paál et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Openings between defective endothelial cells explain tumor vessel leakiness
H Hashizume et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
